学术探索
学术期刊
新闻热点
数据分析
智能评审

Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: A phase II study of the genitourinary group of the French Federation of Cancer Centers

被引：64
作者：
Escudier, B [1 ]
Droz, JP
Rolland, F
Terrier-Lacombe, MJ
Gravis, G
Beuzeboc, P
Chauvet, B
Chevreau, C
Eymard, JC
Lesimple, T
Merrouche, Y
Oudard, S
Priou, F
Guillemare, C
Gourgou, S
Culine, S
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Ctr Leon Berard, Lyon, France
[3] Ctr Rene Gauducheau, Nantes, France
[4] Inst Paoli Calmettes, Marseille, France
[5] Inst Curie, Paris, France
[6] Hop Hotel Dieu, Paris, France
[7] Clin Sainte Catherine, Avignon, France
[8] Inst Claudius Regaud, Toulouse, France
[9] Ctr Eugene Marquis, Rennes, France
[10] Inst Jean Godinot, Reims, France
[11] Ctr Hosp Univ, Besancon, France
[12] Ctr Hosp, La Roche, France
[13] Ctr Val Aurelle, Montpellier, France
来源：
JOURNAL OF UROLOGY | 2002年 / 168卷 / 03期
关键词：
kidney; carcinoma; renal cell; doxorubicin; ifosfamide; neoplasm metastasis;
D O I：
10.1016/S0022-5347(05)64551-X
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose: We assessed the efficacy and toxicity of a chemotherapy regimen combining doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma. Materials and Methods: Of the 25 patients included in a prospective multicenter phase II trial 23 were evaluable for efficacy and toxicity studies after pathological review. Results: A median of 3 cycles per patient (range 1 to 8) was administered. No objective response was observed. Median time to progression was 2.2 months and median overall survival was 3.9 months. A single patient died of toxicity. Conclusions: The results do not support the standard use of doxorubicin/ifosfamide chemotherapy in patients with metastatic sarcomatoid renal cell carcinoma.
引用
收藏
页码：959 / 961
页数：3
相关论文
共 16 条
[1]   Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: Case report and review of the literature [J].
Bangalore, N ;
Bhargava, P ;
Hawkins, MJ ;
Bhargava, P .
ANNALS OF ONCOLOGY, 2001, 12 (02) :271-274
[2]   Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy [J].
Cangiano, T ;
Liao, J ;
Naitoh, J ;
Dorey, F ;
Figlin, R ;
Belldegrun, A .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :523-528
[3]   Sarcomatoid renal cell carcinoma: basic biology, clinical behavior and response to therapy [J].
Chao, D ;
Zisman, A ;
Freedland, SJ ;
Pantuck, AJ ;
Said, JW ;
Belldegrun, AS .
UROLOGIC ONCOLOGY, 2001, 6 (06) :231-238
[4]   TREATMENT OF SARCOMATOID RENAL-CELL CARCINOMA - IS THERE A ROLE FOR CHEMOTHERAPY [J].
CULINE, S ;
BEKRADDA, M ;
TERRIERLACOMBE, MJ ;
DROZ, JP .
EUROPEAN UROLOGY, 1995, 27 (02) :138-141
[5]   Sarcomatoid differentiation in renal cell carcinoma - A study of 101 cases [J].
de Peralta-Venturina, M ;
Moch, H ;
Amin, M ;
Tamboli, P ;
Hailemariam, S ;
Mihatsch, M ;
Javidan, J ;
Stricker, H ;
Ro, JY ;
Amin, MB .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (03) :275-284
[6]   CHEMO-IMMUNOTHERAPY OF SARCOMATOID RENAL-CELL CARCINOMA [J].
KRUTCHIK, AN ;
SULLIVAN, C ;
SINKOVICS, JG ;
AYALA, A .
MEDICAL AND PEDIATRIC ONCOLOGY, 1978, 5 :9-13
[7]   PHASE-II TRIAL OF COMBINATION CHEMOTHERAPY WITH DACARBAZINE, CYCLOPHOSPHAMIDE, CISPLATIN, DOXORUBICIN, AND VINDESINE (DECAV) IN ADVANCED RENAL-CELL CANCER [J].
LUPERA, H ;
COURT, BH ;
THEODORE, C ;
WIBAULT, P ;
GHOSN, M ;
DROZ, JP .
UROLOGY, 1989, 34 (05) :281-283
[8]   Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma [J].
Mian, BM ;
Bhadkamkar, N ;
Slaton, JW ;
Pisters, PWT ;
Daliani, D ;
Swanson, DA ;
Pisters, LL .
JOURNAL OF UROLOGY, 2002, 167 (01) :65-70
[9]  
MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
[10]  
2-6
12